美通社

2024-08-05 21:52

META Pharmaceuticals announces FDA Grants Rare Pediatric Disease Designation to META-001-PH for the Treatment of Primary Hyperoxaluria

HONG KONG, Aug. 5, 2024 /PRNewswire/ -- META Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to its investigational new drug META-001-PH for the treatment of primary hyperoxaluria (PH). Primary hyperoxaluria is a rare genetic disorder that can lead to kidney stone formation, renal failure, and can be life-threatening in severe cases. The RPDD is intended to facilitate the development of drugs and biologics for serious and life-threatening rare pediatric diseases that affect fewer than 200,000 people in the U.S. and predominantly occur in patients aged 18 years and younger. This designation is pursuant to section 529(a)(3) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360ff(a)(3)).

About Primary Hyperoxaluria (PH)

Primary Hyperoxaluria (PH) is an autosomal recessive metabolic disorder in which oxalate is overproduced and deposited in the body due to defects in enzymes responsible for oxalate metabolism in the liver and other organs. Patients typically present with kidney stones, nephrocalcinosis, renal failure, and oxalate deposition in other organs. Severe cases can lead to end-stage renal disease (ESRD) requiring dialysis, kidney transplantation, or combined liver-kidney transplantation. Symptoms of the disease usually appear at the age of 0 to 3. Without intervention, most patients will develop end-stage renal disease during adolescence, which severely threatens their lives. The incidence of PH is estimated to be 1/58,000, affecting more than 10,000 people in the United States and the European Union, and more than 20,000 people in China. Currently, there is no cure for primary hyperoxaluria. Existing treatments are primarily supportive care, including increased fluid intake to dilute oxalate in the urine, and medications such as pyridoxine (vitamin B6) to reduce oxalate production. However, patients' symptoms and disease progression cannot be effectively controlled.

About META-001-PH

META-001-PH is a groundbreaking small molecule drug developed by META for the treatment of primary hyperoxaluria. This innovative molecule is the product of a collaborative effort between META's chemistry team and XtalPi's (2228.HK) AI drug discovery team, who worked together from the initial scaffold screening to the preclinical compound nomination. XtalPi's automated robotic chemical synthesis lab was responsible for the chemical synthesis of the related molecule series, ensuring a precise and efficient production process. Preclinical experiments in animal disease models have shown that META-001-PH can significantly reduce urinary oxalate excretion by up to 80%. While existing therapeutic agents are unable to effectively control urinary oxalate levels in the long term, META-001-PH, administered orally daily, can maintain oxalate at normal levels, thus demonstrating the potential for better long-term control of kidney stone formation in patients with PH. META-001-PH has also demonstrated good tolerability and safety in preclinical animal models and is undergoing IND-enabling toxicology studies with a clinical Phase I safety assessment on healthy subjects planned for 2025H1 in Australia. This collaboration between META and XtalPi marks a significant advancement in the development of effective treatments for primary hyperoxaluria.

About Rare Pediatric Disease Designation (RPDD)

The Rare Pediatric Disease Designation (RPDD) is an eligibility determination for rare pediatric diseases that affect fewer than 200,000 patients and pose a serious life-threatening risk to children under the age of 18. The RPDD and Priority Review Voucher (PRV) program aims to recognize the significant need for therapies for rare pediatric diseases and to encourage the development of new treatments for these serious or life-threatening conditions. Under the program, sponsors will be eligible to receive a PRV upon approval of a New Drug Application (NDA) or Biologics License Application (BLA) for a rare pediatric disease. PRVs can be used for any subsequent product approval application, reducing the review time by 4-6 months, or can be traded with an average transfer price of more than $100 million in recent years.

About META Pharmaceuticals Inc.

META Pharmaceuticals Inc. (META) is an innovative biopharmaceutical company dedicated to discovering and developing urgently needed breakthrough treatments for a broad range of autoimmune disorders, metabolic diseases, and cancer. As the only company in the Asia Pacific Region leveraging the groundbreaking theory of immuno-metabolism, META leads the way in creating safer and more effective therapies that modulate cellular metabolism to regulate immune system function and other pathways. META has developed two distinct chemical series targeting META-001 for the treatment of autoimmune diseases and primary hyperoxaluria, respectively, which hold the potential to become the next-generation oral treatments for these conditions, addressing significant unmet clinical needs. META Pharmaceuticals Inc. is jointly incubated by XtalPi (2228.HK), the leader in the AI-pharmaceutical industry, Forcefield Ventures, and IMO Ventures, with investments from Tiantu Capital (1973.HK), Yael Capital, Fangyuan Capital, Lead Rich International, Decent Capital, and Bopu Capital. For more information, please visit http://en.metabiopharma.com/ and follow us on LinkedIn

Contact: contact@metabiopharma.com

source: Meta Pharmaceuticals Inc.

【你點睇?】馬斯克劍指美國國家民主基金會(NED),籲網民找出「罪證」。你認為若NED遭關閉,是否可促進全球和平穩定?► 立即投票

人氣文章
最近7天
1
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
2
高息定存 | 一周高息合集,銀行高息搶存,富邦1個月4.88厘,華僑1年期3.6厘
3
PapaHome淘寶家具實體店22日開幕,選址尖沙咀中港城,料創100個就業機會
4
高息定存 | 華僑銀行推新春港元定存優惠,88天或188天享3.68厘
5
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
6
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
7
啟德體育園明天足球賽測試,4.4萬公僕參與涉逾400萬車馬費
8
電騙 | 黃俊碩:多管齊下,防治內地留學生受騙
9
環球央行 | 歐洲央行宣布再次減息0.25厘,符合市場預期
10
一本萬利 | 2025年的五個「勿」(有片)
11
易經看世界 | 乙巳蛇年趨吉五招:言行注意甚麼?應遠離甚麼人?(有片)
12
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
13
高息定存 | 一周高息合集,減息預期降溫,銀行3個月最高5.68厘,6個月3.55厘
14
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
15
【FOCUS】螺絲殼裏做道場,DeepSeek致勝啟示
16
大S | 台灣藝人徐熙媛因流感併發肺炎逝世,享年48歲
17
DeepSeek推出即上蘋果中國區榜首,能力直追OpenAI
18
【FOCUS】悟空、哪吒、DeepSeek,如何啟示香港
19
日入而息 | 習近平據報下周見科企領袖,證監會審視8券商孖展風控,大酒店轉蝕9億
20
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
21
新世界 | 摩通:新世界若債務違約或打開行業「潘朵拉盒子」
22
港股 | 午市前瞻 | AI應用概念炒作有錢途 下階段部署邊隻好?
23
【FOCUS】侵侵呼籲全球「降息」,日銀祭18年最激進加息
24
彭博亞洲20大富裕家族,香港5大家族上榜,新地郭氏排名最高,無李嘉誠李兆基?
25
港股 | 蕭猷華:春節假後,恒指逐步上望21000點
26
高息定存 | 信銀國際12個月港元定存高達3.5厘
27
神州經脈 | 特朗普或與華討論關稅,人民幣大漲,滬指連升兩周
28
David Webb:因病情惡化,將有序結束個人財經網站
29
民營企業座談會 | 習近平在京出席民營企業座談會
30
AI | 蔡崇信確認阿里與蘋果合作,撰文談DeepSeek崛起帶來兩大啟示
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

etnet榮膺「第九屆傳媒轉型大獎」四大獎項

【限時優惠$68/月】申請etnet強化版MQ手機串流報價服務 捕捉板塊輪動,提高獲利勝算

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

2025-26年度財政預算案

大國博弈

貨幣攻略

說說心理話

Watch Trends 2024

北上食買玩

Art Month 2024

理財秘笈

流感高峰期

山今養生智慧

輕鬆護老